N/A
Manufactured by Allergan, Inc.
13,196 FDA adverse event reports analyzed
Last updated: 2026-04-14
CARIPRAZINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Allergan, Inc.. The most commonly reported adverse reactions for CARIPRAZINE include OFF LABEL USE, DRUG INEFFECTIVE, WEIGHT INCREASED, AKATHISIA, ANXIETY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARIPRAZINE.
Out of 8,570 classified reports for CARIPRAZINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,196 FDA FAERS reports that mention CARIPRAZINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, WEIGHT INCREASED, AKATHISIA, ANXIETY, TARDIVE DYSKINESIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Allergan, Inc. in connection with CARIPRAZINE. Always verify the specific product and NDC with your pharmacist.